In nature, immune cells deliver a toxic payload to eliminate diseased cells
We use immune cells to deliver therapeutic proteins directly to the cytoplasm of diseased cells to improve patient health.
Roughly two thirds of our body’s proteins are inside cells. These include many key disease pathway targets
Existing therapeutic approaches are limited by tissue tropism, toxicity or payload size
No currently-available technology can introduce a functional protein into a cell, and very few can target a specific tissue
Plug And Play Technology
Plug And Play Technology
Compatible with allogeneic approaches.
Shown to work with T-cells, NK cells.
Creating new modalities
for intracellular therapy
Creating new modalities
for intracellular therapy
is an internationally recognized expert in T-cell therapy and immunotherapy. He brings over 25 years of experience and expertise in cell therapy, including C-level and executive roles at Janssen, Eli Lilly and ArsenalBio,and is a co-inventor of the CART-19 technology from the University of Pennsylvania.
Columbia University
